Optimal Dosing With Risperidone: Updated Recommendations
J Clin Psychiatry 2001;62:282-289
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Drug dosages utilized during
controlled clinical trials are not always optimal for patients
encountered in day-to-day practice. The original trials of
risperidone, a novel antipsychotic, suggested that an initial
target dose of 6 mg/day was appropriate, but these trials were
necessarily conducted among patients who were chronically
impaired, hospitalized, and often partly drug resistant.
Data Sources: Relevant data relating to the
dosage of risperidone identified through an online (MEDLINE)
search using the keywords risperidone, schizophrenia,
schizoaffective disorder, dementia, bipolar
disorder, and dose were supplemented by a review of
international and U.S. Congress abstracts in which the dose of
risperidone was specifically described.
Conclusion: On the basis of naturalistic
studies, clinical audit, phase 4 trials, positron emission
tomography data, and 5 years of clinical experience, the
currently recommended target dose of risperidone is 4 mg/day for
most patients, with less-rapid titration than previously
recommended. Moreover, a lower dose than this and slower
titration may be appropriate for elderly patients, young
patients, and first-episode patients.